JP2001510794A - レボブピバカインとその使用 - Google Patents
レボブピバカインとその使用Info
- Publication number
- JP2001510794A JP2001510794A JP2000503830A JP2000503830A JP2001510794A JP 2001510794 A JP2001510794 A JP 2001510794A JP 2000503830 A JP2000503830 A JP 2000503830A JP 2000503830 A JP2000503830 A JP 2000503830A JP 2001510794 A JP2001510794 A JP 2001510794A
- Authority
- JP
- Japan
- Prior art keywords
- surgery
- levobupivacaine
- block
- motor
- bupivacaine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 title claims abstract description 39
- 229960004288 levobupivacaine Drugs 0.000 title claims abstract description 37
- 238000001356 surgical procedure Methods 0.000 claims abstract description 29
- 230000001953 sensory effect Effects 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 230000003444 anaesthetic effect Effects 0.000 claims description 5
- LEBVLXFERQHONN-MRXNPFEDSA-N dextrobupivacaine Chemical compound CCCCN1CCCC[C@@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-MRXNPFEDSA-N 0.000 claims description 4
- 230000003187 abdominal effect Effects 0.000 claims description 3
- 230000000399 orthopedic effect Effects 0.000 claims description 3
- 206010019909 Hernia Diseases 0.000 claims description 2
- 238000007486 appendectomy Methods 0.000 claims description 2
- 238000002316 cosmetic surgery Methods 0.000 claims description 2
- 238000002297 emergency surgery Methods 0.000 claims description 2
- 238000002682 general surgery Methods 0.000 claims description 2
- 238000009802 hysterectomy Methods 0.000 claims description 2
- 238000007483 tonsillectomy Methods 0.000 claims description 2
- 238000007631 vascular surgery Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 24
- 229960003150 bupivacaine Drugs 0.000 description 20
- 229940079593 drug Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 210000003141 lower extremity Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 6
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical class CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 4
- 229960001549 ropivacaine Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 210000003489 abdominal muscle Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 231100000457 cardiotoxic Toxicity 0.000 description 2
- 230000001451 cardiotoxic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001550 time effect Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229920001821 foam rubber Polymers 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9715322.5 | 1997-07-21 | ||
| GB9715322A GB9715322D0 (en) | 1997-07-21 | 1997-07-21 | Levobupivacaine and its use |
| GBGB9722023.0A GB9722023D0 (en) | 1997-10-17 | 1997-10-17 | Levobupivacaine and its use |
| GB9722023.0 | 1997-10-17 | ||
| PCT/GB1998/002169 WO1999004771A2 (en) | 1997-07-21 | 1998-07-21 | Use of levobupivacaine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001510794A true JP2001510794A (ja) | 2001-08-07 |
| JP2001510794A5 JP2001510794A5 (https=) | 2006-01-05 |
Family
ID=26311915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000503830A Pending JP2001510794A (ja) | 1997-07-21 | 1998-07-21 | レボブピバカインとその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5945435A (https=) |
| EP (1) | EP0998286A2 (https=) |
| JP (1) | JP2001510794A (https=) |
| AU (1) | AU742488B2 (https=) |
| BR (1) | BR9802536A (https=) |
| CA (1) | CA2294950C (https=) |
| WO (1) | WO1999004771A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU752802C (en) | 1997-11-14 | 2006-04-13 | Pacira Pharmaceuticals, Inc. | Production of multivesicular liposomes |
| IL140899A0 (en) | 1998-07-17 | 2002-02-10 | Skyepharma Inc | Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof |
| US6520949B2 (en) * | 2001-04-02 | 2003-02-18 | Martin St. Germain | Method and apparatus for administering fluid to animals subcutaneously |
| AU2002322024B2 (en) * | 2001-05-31 | 2008-05-08 | Pacira Pharmaceuticals, Inc. | Encapsulation of nanosuspensions in liposomes and microspheres |
| US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12151024B2 (en) | 2021-01-22 | 2024-11-26 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| EP4415713A4 (en) | 2021-10-14 | 2025-08-06 | Pacira Pharmaceuticals Inc | MULTIVESICULAR LIPOSOME FORMULATIONS OF BUPIVACAINE AND THEIR USES |
| CN119677554A (zh) | 2022-05-05 | 2025-03-21 | 普络夫有限责任公司 | 麻醉神经阻滞和方法 |
| US12070454B1 (en) | 2022-05-05 | 2024-08-27 | Pfof Llc | Anesthetic nerve block and method |
| US12251472B1 (en) | 2024-05-20 | 2025-03-18 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12156940B1 (en) | 2024-05-20 | 2024-12-03 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12280149B1 (en) | 2024-05-20 | 2025-04-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09503778A (ja) * | 1993-10-13 | 1997-04-15 | カイロサイエンス・リミテッド | 鎮痛剤およびその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695576A (en) * | 1984-07-09 | 1987-09-22 | Astra Lake Medel Aktiebolag | L-N-n-propylpipecolic acid-2,6-xylidide |
| SE9302218D0 (sv) * | 1993-06-28 | 1993-06-28 | Ab Astra | New use |
| AU704806B2 (en) * | 1995-04-13 | 1999-05-06 | Darwin Discovery Limited | Levobupivacaine and its use as an anaesthetic in pregnant women |
| GB9704352D0 (en) * | 1997-03-03 | 1997-04-23 | Chiroscience Ltd | Levobupivacaine and its use |
-
1998
- 1998-07-21 WO PCT/GB1998/002169 patent/WO1999004771A2/en not_active Ceased
- 1998-07-21 US US09/119,910 patent/US5945435A/en not_active Expired - Lifetime
- 1998-07-21 AU AU84527/98A patent/AU742488B2/en not_active Expired
- 1998-07-21 EP EP98935175A patent/EP0998286A2/en not_active Withdrawn
- 1998-07-21 JP JP2000503830A patent/JP2001510794A/ja active Pending
- 1998-07-21 BR BR9802536A patent/BR9802536A/pt not_active Application Discontinuation
- 1998-07-21 CA CA002294950A patent/CA2294950C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09503778A (ja) * | 1993-10-13 | 1997-04-15 | カイロサイエンス・リミテッド | 鎮痛剤およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999004771A3 (en) | 1999-04-08 |
| CA2294950A1 (en) | 1999-02-04 |
| CA2294950C (en) | 2009-04-07 |
| AU742488B2 (en) | 2002-01-03 |
| EP0998286A2 (en) | 2000-05-10 |
| BR9802536A (pt) | 1999-07-20 |
| WO1999004771A2 (en) | 1999-02-04 |
| AU8452798A (en) | 1999-02-16 |
| US5945435A (en) | 1999-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001510795A (ja) | レボブピバカインとその使用 | |
| JP2001510794A (ja) | レボブピバカインとその使用 | |
| PL190896B1 (pl) | Zastosowanie lewobupiwakainy w chirurgii dziecięcej | |
| JP2001513812A (ja) | 顔面手術におけるレボブピバカインの使用 | |
| Madej et al. | Evaluation of “3 in 1” lumbar plexus block in patients having muscle biopsy | |
| JPH09500620A (ja) | 極小の運動遮断で鎮痛効果を示す医薬の製造におけるロピバカインの使用 | |
| Jananimadi et al. | Comparison of postoperative analgesia between intrathecal nalbuphine and intrathecal fentanyl in infraumbilical surgeries: a double-blind randomized controlled trial | |
| Madhusudhanan et al. | Effect of nalbuphine as adjuvant to 0.5% bupivacaine in ultrasoundguided supraclavicular brachial plexus block | |
| Singh et al. | Comparison of low dose ketamine and butorphanol as an adjuvant to propofol for induction in patients undergoing laparoscopic cholecystectomy: A randomized clinical study | |
| Prajwal et al. | Comparison of efficacy and safety of intrathecal ropivacaine-fentanyl and bupivacaine-fentanyl in lower abdominal and lower limb surgeries | |
| Vemuri et al. | Section: Anaesthesiology | |
| Abdelzaam et al. | A comparative study of intrathecal injection of bupivacaine alone or with fentanyl, clonidine, and neostigmine in lower abdominal surgeries | |
| Chandra et al. | Comparison of Bupivacaine (0.5%) and Bupivacaine (0.5%) with Dexmedetomide for Spinal Anesthesia in Lower Abdominal and Pelvic Surgery. | |
| Suntan et al. | Comparison of the efficacy of dexmedetomidine and fentanyl as adjuvants to bupivacaine in arthroscopic knee surgeries. | |
| Ahmad et al. | COMPARATIVE EVALUATION OF CLONIDINE VERSUS TRAMADOL AS ADJUVANT TO EPIDURAL ANAESTHESIA WITH 0.5% BUPIVACAINE FOR LOWER LIMB ORTHOPEDIC PROCEDURES | |
| CA et al. | Comparision of Buprenorphine versus Butorphanol as an adjuvant to intrathecal hyperbaric bupivacaine for elective infraumbilical surgeries: A randomised control study at a tertiary care hospital, Mandya | |
| Anzil | Comparison of intrathecal nalbuphine and fentanyl as an adjuvant to hyperbaric bupivacine for spinal anaesthesia in infraumbilical surgeries: A prospective randomized, double blind study | |
| Valadares et al. | Neostigmine combined or not with lidocaine for epidural anesthesia in mares | |
| MXPA00000397A (es) | Levobupivacaina y su uso | |
| Mandal et al. | A Comparative Study of Intrathecal 0.5% Isobaric Ropivacaine Vs 0.5% Isobaric Bupivacaine in Lower Abdominal Surgeries. | |
| Anjum et al. | COMPARISON OF BUPIVACAINE AND BUPIVACAINE WITH NALBUPHINE FOR SUB ARACHNOID BLOCK IN LOWER ABDOMINAL SURGERIES. | |
| Deusecar et al. | Low dose spinal with chlorprocaine a prospective observational study | |
| Interlandi et al. | Evaluation of the effects of a single bolus of cisatracurium as part of an anesthetic protocol in cats undergoing orthopedic surgery. | |
| Madsen et al. | A comparison of epidural narcotics, with and without a test dose, to epidural lidocaine for extracorporeal shock wave lithotripsy | |
| Haque et al. | The Clinical Efficacy of Hyperbaric Solution of Ropivacaine (0.5%) With Hyperbaric Bupivacaine (0.5%) in Spinal Anaesthesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050712 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050712 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090526 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090826 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100831 |